Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.

What It Covers

This systematic review looks at Elafin.

Graft versus host disease (GVHD) is the common complication seen after allogeneic hematopoietic stem cell transplantation (HSCT) and a pleomorphic syndrome that resembles autoimmune and other immunologic disorders, leading to profound immune dysregulation and organ dysfunction.

The most common targets of GVHD are skin, gastrointestinal tract and liver.

GVHD is classified as acute graft versus host disease (aGvHD) if it occurs within the first 100 days after HSCT and chronic graft versus host disease(cGVHD) if it occurs after day 100.

Who the Included Studies Covered

After selecting the study based on inclusion criteria, data on study characteristics and biomarker description was extracted on a pre-determined data extraction table on the Microsoft Excel version.

The quality assessment of the included studies was determined using the QUIPS tool.

How the Review Was Done

The researchers searched the databases PubMed, Cochrane library, and medRxiv for all studies investigating the Diagnostic or prognostic role of elafin in GVHD.

The researchers set the search strategy incorporating the search terms, 'elafin', 'graft versus host', and 'GVHD', and operated using the Boolean operators 'AND', and 'OR'.

Thus, retrieved articles were then exported on an Excel® sheet, and duplicates were removed.

The systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

What Was Measured

The subject headings attached to it are Prognosis, Elafin, Hematopoietic Stem Cell Transplantation, Biomarkers, Graft vs Host Disease and Acute Disease.

Author keywords: HSCT, aGVHD, graft versus host; GVHD and systematic review.

What This Means in Plain Language

This is a systematic review of Elafin.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Hematology (Amsterdam, Netherlands)), a journal based in England.

More context: the Elafin compound page, all human trials.